Compare CMTL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | CRDF |
|---|---|---|
| Founded | 1967 | 1999 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 130.7M |
| IPO Year | 2024 | 2012 |
| Metric | CMTL | CRDF |
|---|---|---|
| Price | $3.85 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $9.63 |
| AVG Volume (30 Days) | 171.2K | ★ 615.8K |
| Earning Date | 06-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.71 | $1.48 |
| 52 Week High | $6.21 | $4.56 |
| Indicator | CMTL | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 49.62 |
| Support Level | $2.78 | $1.51 |
| Resistance Level | $4.24 | $1.68 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 64.66 | 50.00 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.